ACER3 enzyme may be therapeutic target in cholestasis: Lab study
ACER3, an enzyme involved in the metabolism of fat-like signaling molecules known as ceramides, plays a detrimental role in cholestasis-related liver damage — and,…
Cholestasis
Cilnidipine, bexarotene ease liver damage in rat model of cholestasis
Preventive treatment with cilnidipine and bexarotene significantly reduced markers of inflammation, liver damage, and oxidative stress, a type of cellular damage, in a rat model…
RTY-694 shows promise in models of liver, bile duct diseases PFIC, PSC
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
Air pollution may raise intrahepatic cholestasis of pregnancy risk
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
New PFIC3-causing mutations identified in 3 children in China
A study of three children with progressive familial intrahepatic cholestasis type 3 (PFIC3) in China revealed that different disease-causing mutations in the ABCB4 gene,…
AI model may predict cholestasis-related cognitive impairment risk
An artificial intelligence (AI) model can accurately discriminate between cholestasis patients with and without moderate to severe disease-associated cognitive impairment based on 13 possible…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Telling our 4-year-old that she has familial ‘tummy trouble’
I’ve often wondered how and when we’ll tell our daughter Eva that she has progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. Most…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
FDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
